Multimodal endoscopy represents a transformative leap in the future of medical diagnostics and therapy by integrating multiple imaging and sensing techniques into a single platform. By combining modalities such as high-resolution optical imaging, fluorescence detection, and spectroscopic analysis, it enables clinicians to obtain comprehensive, real-time information about tissue structure, function, and biochemical composition. This synergistic approach enhances early disease detection—particularly for cancers—while improving diagnostic accuracy and guiding targeted interventions. As technology advances, multimodal endoscopy is poised to move beyond diagnosis toward theranostics, where imaging and treatment are seamlessly integrated, ultimately leading to more personalized, efficient, and minimally invasive healthcare solutions.

“Multimodal endoscopy is not merely an evolution of imaging technologies, but a paradigm shift in medicine—where seeing, understanding, and treating disease converge in real time, opening the path toward truly personalized and predictive healthcare.”

Multimodal endoscopy represents a significant paradigm shift because it overcomes one of the fundamental limitations of conventional endoscopy: the reliance on morphology alone. Traditional systems provide high-resolution structural images, but they often miss early-stage or subtle biochemical changes that precede visible lesions. By integrating multiple optical and functional techniques into a single probe, multimodal platforms enable a more comprehensive, layered understanding of tissue—combining anatomy, physiology, and molecular composition in real time.

A key example is the integration of white-light imaging with fluorescence endoscopy. While white-light imaging reveals macroscopic structures, fluorescence can highlight specific biomarkers or metabolic activity. For instance, in gastrointestinal oncology, fluorescent probes can selectively bind to dysplastic or cancerous cells, allowing clinicians to detect lesions that would otherwise remain invisible. This dual-modality approach significantly improves early detection rates and reduces false negatives.

Another powerful combination involves nonlinear optical techniques such as second harmonic generation (SHG), two-photon fluorescence, and coherent Raman scattering (including CARS and stimulated Raman scattering). These label-free methods provide subcellular resolution and intrinsic chemical contrast without the need for external dyes. For example, SHG is highly sensitive to collagen architecture, making it valuable for identifying early stromal remodeling in cancer progression. Meanwhile, Raman-based modalities can map lipid and protein distributions, offering insight into metabolic alterations associated with disease. When integrated into fiber-based probes, these techniques enable in vivo “optical biopsies,” reducing the need for invasive tissue excision.

A particularly forward-looking development is the coupling of multimodal imaging with therapeutic functionalities, such as laser ablation or cold atmospheric plasma delivery. In such systems, diagnosis and treatment are no longer separate steps: suspicious tissue can be identified, characterized, and immediately treated within the same procedure. This concept of “see-and-treat” endoscopy is especially promising for minimally invasive oncology, where precision and speed are critical.

From a technological perspective, achieving true multimodality requires advances in ultrafast laser sources, specialty optical fibers (including nonlinear and multicore fibers), and miniaturized detection systems. The challenge lies not only in integrating these components into a compact, flexible probe, but also in managing data fusion—combining multiple data streams into a coherent, clinically useful output. Artificial intelligence is expected to play a crucial role here, assisting in real-time interpretation and decision support.

In analysis, the impact of multimodal endoscopy can be viewed across three dimensions. First, diagnostic accuracy: combining modalities reduces ambiguity and improves sensitivity and specificity. Second, clinical workflow: real-time, in situ characterization shortens diagnostic pathways and may eliminate the need for separate histopathology in some cases. Third, patient outcomes: earlier detection and immediate intervention translate into less invasive treatments, reduced healthcare costs, and improved survival rates.

Final considerations

Despite these advantages, challenges remain. System complexity, cost, regulatory approval, and the need for clinician training are nontrivial barriers. Moreover, ensuring robustness and reproducibility in a clinical environment is essential for widespread adoption. Nevertheless, as these hurdles are progressively addressed, multimodal endoscopy is poised to redefine the standard of care—transforming endoscopes from passive imaging tools into intelligent platforms for comprehensive diagnosis and targeted therapy.